This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 594Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
2051 | EpCAM | Protein | Human | Upregulated for CTCs in patients with HCC. | Diagnostic | HCC v/s Normal | p = 0.595 | Blood | 27034142 |
2052 | EMA | Protein | Human | Upregulated for CTCs in patients with HCC. | Diagnostic | HCC v/s Normal | p < 0.05 | Blood | 27034142 |
2053 | CFL1 | Protein | Human cell lines and Mice | Upregulated in HBV-HCC | Diagnostic and Prognostic | HBV-HCC vs normal | p < 0.05 | Tissue | 27708241 |
2054 | ADFP | Protein | Human cell lines and Mice | Upregulated in HBV-associated HCC | Diagnostic and Prognostic | HBV-HCC vs normal | p < 0.05 | Tissue | 27708241 |
2055 | TRIM32 | Protein | Human | Upregulated in HCC tumor tissues and HCC cell lines. | Diagnostic and Prognostic | HCC v/s Normal; significant predictor for the overall survival time of HCC patients and positively correlated with histological grade, tumor sizes of patients | p < 0.05 | Tissue | 27573002 |
2056 | Putrescine, spermidine, spermine, N-acetylspermine and N-acetylspermidine | Metabolite | Human | Upregulated in the plasma of liver cancer patients than lung cancer patients | Diagnostic | HCC v/s Normal | p < 0.05 | Urine and Plasma | 27517900 |
2057 | Spermine, followed by N-acetylspermidine, putrescine, cadaverine, spermidine, N-acetylspermine and N-acetylputrescine | Metabolite | Human | Upregulated in the urine of liver cancer patients than lung cancer patients | Diagnostic | HCC v/s Normal | p < 0.05 | Urine and Plasma | 27517900 |
2058 | HIF1A | Protein | Human | Upregulated in at both an mRNA and protein level in patients with PLC | Diagnostic and Prognostic | Cancer v/s Normal; predict survival of patients | p < 0.05 | Tissue | 27173353 |
2059 | VEGF | Protein | Human | Upregulated in at both an mRNA and protein level in patients with PLC | Diagnostic and Prognostic | Cancer v/s Normal; predict survival of patients | p < 0.05 | Tissue | 27173353 |
2060 | Uracil | Metabolite | Mice | Downregulated | Potential Predictive * | Cancer v/s Normal; Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2061 | cis-Aconitate acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2062 | D-4-Phosphopantothenate | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2063 | Progesterone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2064 | 5-Thymidylic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2065 | 2-Phospho-d-glyceric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2066 | Niacinamide | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2067 | Cortisone | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2068 | Imidazoleacetic acid ribotide | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2069 | 3-Methyl-2-oxovaleric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2070 | Pseudoephedrine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2071 | 4-Phosphopantothenoylcysteine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2072 | Pantetheine 4-phosphate | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2073 | Hippuric acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2074 | 3-Hydroxyanthranilic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2075 | Glycine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2076 | Creatine | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2077 | Cortisol | Metabolite | Mice | Upregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2078 | Allantoic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2079 | Pantothenic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2080 | Creatinine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2081 | Urea | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2082 | 5-Hydroxyindoleacetic acid | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2083 | Phytosphingosine | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.05 | Urine and Plasma | 27077962 |
2084 | Imidazoleacetic acid riboside | Metabolite | Mice | Downregulated | Potential Predictive * | Drug treated group v/s control group | p < 0.01 | Urine and Plasma | 27077962 |
2085 | Estrogen , Estradiol, AFP | Protein + Steroid | Human | Downregulated in liver cancer cell. | Diagnostic | Normal vs liver cancer | p < 0.05 | Serum | 27060391 |
2086 | Estrone plus Estradiol/Testosterone ratio | Steroid | Human | Downregulated in liver cancer cell. | Diagnostic | Normal vs liver cancer | p < 0.06 | Serum | 27060391 |
2087 | AFP | Protein | Human | Downregulated in liver cancer cell. | Diagnostic | Normal vs liver cancer | p < 0.06 | Serum | 27060391 |
2088 | Aspartate aminotransferase to white blood cell count ratio (AWR) | Others | Human | AWR > 5.2 was an adverse predictor of DFS and OS in HCC after hepatectomy | Prognostic | HCC patients with AWR >5.2 v/s HCC patients with AWR <5.2; predict survival of patients | p < 0.01 | Blood | 27057915 |
2089 | miR-200c | miRNA | Human | Downregulated in PSC with control | Diagnostic | Normal v/s cancer v/s PSC | p < 0.05 | Serum | 26864161 |
2090 | miR-483-5p | miRNA | Human | Upregulated in CC compared with controls and PSC. | Diagnostic | Normal vs cancer | p < 0.05 | Serum | 26864161 |
2091 | miR-194 | miRNA | Human | Upregulated in CC compared with controls. | Diagnostic | Normal vs cancer | p < 0.05 | Serum | 26864161 |
2092 | DLC1 | RNAs | Human | Downregulated in HCC | Prognostic | Cancer v/s Normal; predict survival of patients | p < 0.05 | Tissue | 26846339 |
2093 | miR-122 | miRNA | Human | Upregulatd in chronic HCV v/s healthy control (with log fold change 3.17) | Diagnostic | Cancer v/s Normal | p < 0.05 | Serum | 26812693 |
2094 | miR-222 | miRNA | Human | Upregulatd in chronic HCV v/s healthy control (with log fold change 3.11) | Diagnostic | Cancer v/s Normal | p < 0.01 | Serum | 26812693 |
2095 | IRF1 | RNAs | Human | Upregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Cancer v/s Normal | FDR <0.01 | Cells | 26811688 |
2096 | GBP1 | RNAs | Human | Upregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2097 | ICAM1 | RNAs | Human | Upregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2098 | Foxa1 | RNAs | Human | Downregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2099 | DHCR7 | RNAs | Human | Downregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |
2100 | HMGCS2 | RNAs | Human | Downregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) | Diagnostic | Normal vs HCC | FDR <0.01 | Cells | 26811688 |